Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesCA 19-9 as a biomarker in advanced pancreatic cancer patients randomised to gemcitabine plus axitinib or gemcitabine alone
British Journal of Cancer, 09/03/09
Wasan HS et al. – Baseline CA 19-9 levels had prognostic value for OS, but caution is advised in interpreting CA 19-9 as a predictive biomarker for novel cytostatic agents such as VEGF-targeted therapies.
Methods- Serum CA 19-9, clinical outcomes and DBP in 95 APC patients receiving gemcitabine plus axitinib (Gem+A) or gemcitabine alone
- Median OS was significantly longer in patients with baseline CA 19-9 values at or below the median than in those with values above it (12.2 mos vs 5.0 mos)
- Significance was also reached in the Gem+A arm (median OS, 12.5 mos vs 4.9 mos)
- Patients with a DBP>90 mmHg had significantly longer OS than those who did not
Related Articles
A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic NSCLC
Annals of Oncology, 10/19/09
Relevance Score: 69%
Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer
Journal of Clinical Oncology, 11/13/09
Relevance Score: 68%
Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer
Journal of Clinical Oncology, 11/03/09
Relevance Score: 68%
Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer
Journal of Clinical Oncology, 10/29/09
Relevance Score: 67%
Feasibility study for biweekly administration of cisplatin plus gemcitabine as adjuvant-chemotherapy for completely resected non-small cell lung cancer
Cancer Chemotherapy and Pharmacology, 10/14/09
Relevance Score: 65%
Today in Basic Science/Genetics...keeping you current
Receive free subspecialty "5-minute updates" via email
Mutation analysis of the MSMB gene in familial prostate cancer
British Journal of Cancer, 12/10/09
Influence of omega-6 PUFA arachidonic acid and bone marrow adipocytes on metastatic spread from prostate cancer
British Journal of Cancer, 12/10/09
Gene set enrichment analysis provides insight into novel signalling pathways in breast cancer stem cells
British Journal of Cancer, 12/10/09
Today in Hepatobiliary/Pancreas...keeping you current
Receive free subspecialty "5-minute updates" via email
Depth of invasion determines the postresectional prognosis for patients with T1 extrahepatic cholangiocarcinoma
Cancer, 12/10/09
Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the Arbeitsgemeinschaft Internistische Onkologie
Anti-Cancer Drugs, 12/10/09
Autophagy Is Activated by TGF-beta and Potentiates TGF-beta–Mediated Growth Inhibition in Human Hepatocellular Carcinoma Cells
Cancer Research, 12/09/09
Sponsor
Article Search
Sponsor
Sponsor